Recently, Shanghai Yanan Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), a holding subsidiary of Shanghai Yanan Pharmaceutical Yangpu Co., Ltd., commissioned Tianjin Junan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Tianjin Junan") to complete the consistency evaluation of the product grid After passing the consistency evaluation on December 23, 2020, Qite Sustained Release Tablets will participate in the fourth batch of national organizations organized by the National Organization for Centralized Procurement and Use of Drugs and the Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") on February 3, 2021. Bidding for centralized drug procurement (hereinafter referred to as "this centralized procurement").
According to the "Notice on Announcement of the Selection Results of National Drug Centralized Procurement" issued by the Joint Procurement Office on February 8, 2021, Tianjin Junan Product Gliclazide Sustained-Release Tablets (30mg) was selected for this centralized procurement, and the relevant bids will now be won The situation announcement is as follows:
1. The basic situation of the winning product
1. Name of drug: Gliclazide sustained-release tablets;
2. Specification: 30mg×15 pieces/plate×4 plates/box;
3. Procurement cycle: 2 years
The selected prices, purchase quantities, and supply provinces (regions) are subject to the announcement on the Shanghai Sunshine Pharmaceutical Purchasing Network.
2. The impact of winning the bid on the company
In accordance with the agreement signed by the company and Tianjin Junan in the technology development commission contract, after Tianjin Junan has completed the consistency evaluation of gliclazide sustained-release tablets, the product will be transferred to the company's name through the transfer of the drug marketing license holder . This centralized procurement is the fourth batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to using the drugs selected in this centralized drug procurement and ensure that the agreed procurement volume is completed. After the company has confirmed the selection, signed the purchase and sale contract and implemented it, it will further enhance the visibility and influence of the company's products, and lay a good foundation for the market promotion of other products. At the same time, the company will actively practice the basic purpose of serving more diabetic patients, strive to provide patients with more and higher-quality products, and contribute to the company's mission of human health and happiness.
Three, risk warning
At present, Tianjin Junan has signed the "Memorandum of National Drug Centralized Procurement Proposed Varieties" with the United Procurement Office. The follow-up matters such as the signing of the procurement contract for the above-mentioned products and the implementation of market sales after mass procurement are still uncertain. The company will pay close attention to the progress of this matter and timely perform its information disclosure obligations in accordance with relevant laws and regulations. Investors are requested to make cautious decisions and pay attention to investment risks.
      Special announcement.

Shanghai Yan'an Pharmaceutical Yangpu Co., Ltd.
Board of Directors
February 9, 2021